NCT07383649 2026-02-03
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
The Methodist Hospital Research Institute
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT07294547 2025-12-19
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
National Taiwan University Hospital
Phase NA Recruiting
NCT06102525 2025-09-05
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Rznomics, Inc.
Phase 1/2 Recruiting
NCT07138989 2025-08-24
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT00478465 2022-05-27
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Stanford University
Phase 1/2 Completed
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT00400322 2021-03-01
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
Karolinska Institutet
Phase NA Completed
NCT00387530 2019-08-02
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
University of California, San Diego
Phase 2 Withdrawn
NCT02761291 2016-05-16
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
Chang Gung Memorial Hospital
Phase 1 Unknown
NCT01255644 2015-07-21
VGCV-CLL
Medical University of Vienna
Phase 4 Completed
NCT00562770 2012-07-31
Oral Valganciclovir Versus Valacyclovir
M.D. Anderson Cancer Center
Phase 2 Completed